"Cell"

The results of a new study show that Ubamatamab, a bispecific antibody drug, has shown excellent results and a good safety profile in patients with ovarian cancer.

Science has published two consecutive research articles that suggest new ways to improve the efficacy of CAR-T for solid tumours.

The US FDA has approved pablizumab (Keytruda) as an adjuvant treatment for early-stage non-small cell lung cancer. In the trial, pablizumab (Keytruda) significantly prolonged cancer-free survival in patients compared to placebo.

Accelerating and simplifying the development and manufacturing process of cell and gene therapies.

A recent study led by the University of Texas Southwestern Medical Center on prostate cancer shows that by stopping the "transformation" of cancer cells in prostate cancer, new treatments are expected to overcome drug resistance.

A cutting-edge study from the University of California, San Francisco, recently showed that researchers have been able to make immune cells, which already recognize cancer cells, more powerful and durable through CRISPR gene editing tools, promising to become tireless, cold-blooded "cancer killers"!